Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

医学 结直肠癌 全直肠系膜切除术 化疗 外科 入射(几何) 卡培他滨 放射科 放化疗 直肠 放射治疗 毒性 辅助化疗 完全响应 临床研究阶段 奥沙利铂 癌症 肿瘤科 氟尿嘧啶 治疗
作者
Wei-Jian Mei,Xiaozhong Wang,Xuan Zhang,Yueming Sun,C Chia-Kai Yang,Jun‐Zhong Lin,Zuguang Wu,Rui Zhang,Wei Wang,Y. Li,Yezhong Zhuang,Jian Lei,Xiang Bin Wan,Yingkun Ren,Yong Cheng,Wen-Liang Li,Ziqiang Wang,Dongbo Xu,Xianwei Mo,Haixing Ju
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (11): 970-980 被引量:12
标识
DOI:10.1200/jco-25-00731
摘要

PURPOSE The neoadjuvant chemoradiotherapy (nCRT) might accentuate surgical complications and toxicity in the treatment of locally advanced rectal cancer (LARC) while neoadjuvant chemotherapy (nCT) alone shows promise as an alternative treatment. However, which patients deserve most from the nCT need further clarify. This trial aimed to assess the non-inferiority of nCT with capecitabine plus oxaliplatin (CAPOX) versus nCRT with capecitabine in LARC with uninvolved mesorectal fascia (MRF). METHODS Patients with LARC within 12 cm from the anal verge and uninvolved MRF were randomly assigned to receive 4 cycles of CAPOX chemotherapy alone (nCT group) or CRT with concurrent Capecitabine (nCRT group). The primary end point is 3-year locoregional recurrence-free survival (LRRFS). Secondary end points, such as 3-year disease-free survival (DFS), 3-year overall survival (OS), and adverse events (AEs), were also reported. RESULTS A total of 663 patients were enrolled and 589 patients received the allocated treatment (nCT, n = 300; nCRT, n = 289). LRRFS was analyzed with a median follow-up of 48 months. 3-year LRRFS was 97.4% (95% CI, 95.5 to 99.3) in the nCRT group and 96.3% (95% CI, 94.0 to 98.6) in the nCT group, resulting in a hazard ratio (HR) of 1.40 (95% CI, 0.53 to 3.68). The nCT and nCRT achieved similar 3-year DFS (89.2% v 87.9%; HR, 0.88 [95% CI, 0.54 to 1.44]) and 3-year OS (95.0% v 94.1%; HR, 0.86 [95% CI, 0.42 to 1.76]). The nCT group showed a lower incidence of grade 2 to 4 long-term AEs (16.0% v 26.3%, P = 0.002) and proctitis (33.6% v 41.7%, P = 0.049) compared with nCRT group. CONCLUSIONS The non-inferiority of nCT was not confirmed with a very low incidence of local recurrence in both group. But nCT offers comparable DFS and OS while mitigating the burden of toxicity as compared to nCRT. These insights shed light on a potential paradigm shift in the treatment for LARC with uninvolved MRF.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马甲的应助被Peter采纳,获得10
2秒前
香蕉觅云的应助被悦耳的芒果采纳,获得10
3秒前
jaeger发布了新的文献求助10
3秒前
4秒前
打打的应助被跑在颖采纳,获得10
5秒前
所所的应助被km采纳,获得10
6秒前
6秒前
SERS小子完成签到,获得积分10
6秒前
rio发布了新的文献求助10
7秒前
彭于晏的应助被细心的凡蕾采纳,获得10
7秒前
fancy完成签到,获得积分10
8秒前
小猫挠屁股完成签到 ,获得积分10
9秒前
9秒前
真实的百川完成签到,获得积分10
9秒前
元吉的应助被zx采纳,获得10
10秒前
领导范儿的应助被寻找布冯采纳,获得10
11秒前
haaaaa完成签到 ,获得积分10
13秒前
13秒前
13秒前
瑾钰满糖完成签到,获得积分10
14秒前
Peter发布了新的文献求助10
14秒前
14秒前
科研通AI6.4的应助被Gg采纳,获得10
15秒前
15秒前
科研通AI6.2的应助被林川采纳,获得30
16秒前
16秒前
WilliamTT发布了新的文献求助10
17秒前
明天完成签到,获得积分10
17秒前
18秒前
molihuakai的应助被激昂的如柏采纳,获得10
20秒前
20秒前
回望发布了新的文献求助10
20秒前
20秒前
yawngale发布了新的文献求助10
20秒前
旧城以西发布了新的文献求助10
21秒前
hhud完成签到 ,获得积分10
21秒前
21秒前
顾矜的应助被Arthur采纳,获得10
22秒前
华仔的应助被洁净的千凡采纳,获得10
22秒前
脑洞疼的应助被喵喵机采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055